PH27105A - Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceutical - Google Patents
Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceutical Download PDFInfo
- Publication number
- PH27105A PH27105A PH41182A PH41182A PH27105A PH 27105 A PH27105 A PH 27105A PH 41182 A PH41182 A PH 41182A PH 41182 A PH41182 A PH 41182A PH 27105 A PH27105 A PH 27105A
- Authority
- PH
- Philippines
- Prior art keywords
- cis
- acid
- agent
- formula
- group
- Prior art date
Links
- 230000004907 flux Effects 0.000 title claims abstract description 20
- 239000003623 enhancer Substances 0.000 title abstract description 6
- 238000011200 topical administration Methods 0.000 title abstract description 6
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 34
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 17
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 16
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000005642 Oleic acid Substances 0.000 claims abstract description 14
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 16
- 235000021313 oleic acid Nutrition 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 231100000223 dermal penetration Toxicity 0.000 claims description 6
- 229960001389 doxazosin Drugs 0.000 claims description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 229960002702 piroxicam Drugs 0.000 claims description 6
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 4
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 claims description 4
- 229940108623 eicosenoic acid Drugs 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 3
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 239000004100 Oxytetracycline Substances 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229960003022 amoxicillin Drugs 0.000 claims description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 229960004099 azithromycin Drugs 0.000 claims description 3
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 229960003722 doxycycline Drugs 0.000 claims description 3
- 229960003276 erythromycin Drugs 0.000 claims description 3
- 229960004884 fluconazole Drugs 0.000 claims description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 3
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001381 glipizide Drugs 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- 229960000905 indomethacin Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229960002009 naproxen Drugs 0.000 claims description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
- 229960001597 nifedipine Drugs 0.000 claims description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960000625 oxytetracycline Drugs 0.000 claims description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 3
- 235000019366 oxytetracycline Nutrition 0.000 claims description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005489 paracetamol Drugs 0.000 claims description 3
- 229940056360 penicillin g Drugs 0.000 claims description 3
- 229960001289 prazosin Drugs 0.000 claims description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 3
- 229960002073 sertraline Drugs 0.000 claims description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 3
- 229960002180 tetracycline Drugs 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 229930101283 tetracycline Natural products 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 229960004214 tioconazole Drugs 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 229930195708 Penicillin V Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229960000528 amlodipine Drugs 0.000 claims description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 229940056367 penicillin v Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- OXEDXHIBHVMDST-SREVYHEPSA-N (z)-octadec-12-enoic acid Chemical compound CCCCC\C=C/CCCCCCCCCCC(O)=O OXEDXHIBHVMDST-SREVYHEPSA-N 0.000 claims 1
- PCEPYENXHJPCEF-UHFFFAOYSA-N 1-decylazepan-2-one Chemical compound CCCCCCCCCCN1CCCCCC1=O PCEPYENXHJPCEF-UHFFFAOYSA-N 0.000 claims 1
- FPAQLJHSZVFKES-NXVVXOECSA-N 5Z-eicosenoic acid Chemical compound CCCCCCCCCCCCCC\C=C/CCCC(O)=O FPAQLJHSZVFKES-NXVVXOECSA-N 0.000 claims 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- YWWVWXASSLXJHU-WAYWQWQTSA-N myristoleic acid Chemical group CCCC\C=C/CCCCCCCC(O)=O YWWVWXASSLXJHU-WAYWQWQTSA-N 0.000 claims 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000000243 solution Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 12
- 230000002500 effect on skin Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 238000012385 systemic delivery Methods 0.000 description 8
- 230000032258 transport Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229910021607 Silver chloride Inorganic materials 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- -1 Nat Chemical class 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VQDOIVGYJXZOQY-KTKRTIGZSA-N (z)-pentadec-6-enoic acid Chemical compound CCCCCCCC\C=C/CCCCC(O)=O VQDOIVGYJXZOQY-KTKRTIGZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RWNNRGBCWXOVAC-UHFFFAOYSA-N 1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine Chemical compound C1CN1P(N1CCN(CC1)P(=O)(N1CC1)N1CC1)(=O)N1CC1 RWNNRGBCWXOVAC-UHFFFAOYSA-N 0.000 description 1
- NDFFLUPUGUDAOM-UHFFFAOYSA-N 1-tetradecylazepan-2-one Chemical compound CCCCCCCCCCCCCCN1CCCCCC1=O NDFFLUPUGUDAOM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NNNVXFKZMRGJPM-UHFFFAOYSA-N 6-Hexadecenoic acid Natural products CCCCCCCCCC=CCCCCC(O)=O NNNVXFKZMRGJPM-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- CATSNJVOTSVZJV-UHFFFAOYSA-N Heptan-2-one Natural products CCCCCC(C)=O CATSNJVOTSVZJV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000005331 crown glasses (windows) Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/443,699 US5023085A (en) | 1989-11-29 | 1989-11-29 | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH27105A true PH27105A (en) | 1993-03-16 |
Family
ID=23761854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH41182A PH27105A (en) | 1989-11-29 | 1990-11-02 | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceutical |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5023085A (da) |
| EP (1) | EP0435436B1 (da) |
| JP (1) | JPH0688912B2 (da) |
| KR (1) | KR930007248B1 (da) |
| AT (1) | ATE99961T1 (da) |
| AU (1) | AU613281B1 (da) |
| CA (1) | CA2030943A1 (da) |
| DE (1) | DE69006000T2 (da) |
| DK (1) | DK0435436T3 (da) |
| HU (1) | HUT55629A (da) |
| IE (1) | IE63597B1 (da) |
| IL (1) | IL96449A (da) |
| MY (1) | MY109727A (da) |
| NZ (1) | NZ236253A (da) |
| PH (1) | PH27105A (da) |
| PT (1) | PT96021B (da) |
| ZA (1) | ZA909512B (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196410A (en) * | 1986-10-31 | 1993-03-23 | Pfizer Inc. | Transdermal flux enhancing compositions |
| DE3880923T3 (de) * | 1987-02-23 | 1997-12-18 | Shiseido Co Ltd | Perkutaner absorptionspromotor und dermatologische zusammensetzung für externe anwendung. |
| US5080646A (en) * | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
| US5262165A (en) * | 1992-02-04 | 1993-11-16 | Schering Corporation | Transdermal nitroglycerin patch with penetration enhancers |
| US5334138A (en) * | 1990-03-15 | 1994-08-02 | North Carolina State University | Method and composition for increased skin concentration of active agents by iontophoresis |
| US5383848A (en) * | 1990-04-12 | 1995-01-24 | Gensia, Inc. | Iontophoretic administration of drugs |
| US6238381B1 (en) | 1990-11-01 | 2001-05-29 | Robert Tapper | Iontophoretic treatment system |
| US6600950B1 (en) * | 1990-11-01 | 2003-07-29 | Robert Tapper | Iontophoretic treatment system |
| US6139537A (en) * | 1990-11-01 | 2000-10-31 | Tapper; Robert | Iontophoretic treatment system |
| US6582416B2 (en) | 1990-11-01 | 2003-06-24 | Robert Tapper | Iontophoretic treatment system |
| US6223076B1 (en) | 1990-11-01 | 2001-04-24 | Robert Tapper | Sweat control system |
| US6575957B1 (en) * | 1990-11-01 | 2003-06-10 | Robert Tapper | Iontophoretic treatment system |
| US6235013B1 (en) | 1990-11-01 | 2001-05-22 | Robert Tapper | Iontophoretic treatment system |
| US5224927A (en) * | 1990-11-01 | 1993-07-06 | Robert Tapper | Iontophoretic treatment system |
| US5131403A (en) * | 1991-06-05 | 1992-07-21 | Becton Dickinson And Company | Method for obtaining blood using iontophoresis |
| US5356632A (en) * | 1991-09-12 | 1994-10-18 | S.I. Scientific Innovations Ltd. | Transdermal drug delivery device |
| ATE169826T1 (de) * | 1992-01-21 | 1998-09-15 | Macrochem Corp | Iontophoretische verbesserte verabreichung von medikamenten |
| ES2112552T3 (es) * | 1992-06-02 | 1998-04-01 | Alza Corp | Dispositivo para la administracion de un medicamento por electrotransporte. |
| US5580574A (en) * | 1994-04-28 | 1996-12-03 | Hoffmann-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO1996002232A1 (en) * | 1994-07-13 | 1996-02-01 | Alza Corporation | Composition and method for enhancing transdermal electrotransport agent delivery |
| US5540654A (en) * | 1994-09-02 | 1996-07-30 | North Carolina State University | Iontophoretic electrode |
| US5736580A (en) * | 1994-11-14 | 1998-04-07 | Alza Croporation | Composition, device, and method for electrotransport agent delivery |
| US5861439A (en) * | 1994-11-14 | 1999-01-19 | Alza Corporation | Method for enhanced electrotransport agent delivery |
| US5990179A (en) * | 1995-04-28 | 1999-11-23 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
| US5985316A (en) * | 1995-04-28 | 1999-11-16 | Alza Corporation | Composition and method of enhancing electrotransport agent delivery |
| US6355025B1 (en) | 1995-06-07 | 2002-03-12 | Alza Corporation | Adjustable electrotransport drug delivery using a fixed output controller |
| WO1997014473A1 (en) * | 1995-10-18 | 1997-04-24 | Novartis Ag | Thermopile powered transdermal drug delivery device |
| US7094422B2 (en) | 1996-02-19 | 2006-08-22 | Acrux Dds Pty Ltd. | Topical delivery of antifungal agents |
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| EP0849265A1 (de) * | 1996-12-20 | 1998-06-24 | HEUMANN PHARMA GmbH | Neue polymorphe Form von Doxazosin-Mesylat (Form II) |
| AUPO907697A0 (en) * | 1997-09-09 | 1997-10-02 | Day, Robert Edward | Chemical supplementation of bone |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| PT1135188E (pt) | 1998-11-02 | 2008-03-19 | Alza Corp | Dispositivo de electrotransporte incluíndo um agente antimicrobiano compatível |
| JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| EP1259286A1 (en) | 2000-02-18 | 2002-11-27 | The University of Utah Research Foundation | Methods for extracting substances using alternating current |
| WO2001060449A1 (en) | 2000-02-18 | 2001-08-23 | University Of Utah Research Foundation | Methods for delivering agents using alternating current |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| US7137975B2 (en) * | 2001-02-13 | 2006-11-21 | Aciont, Inc. | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent |
| WO2002081024A1 (en) * | 2001-04-04 | 2002-10-17 | Alza Corporation | Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition |
| US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US20050220439A1 (en) * | 2004-03-19 | 2005-10-06 | Carton Owen A | Interactive multimedia system and method |
| US20060222692A1 (en) * | 2005-03-31 | 2006-10-05 | Fairfield Clinical Trials Llc | Method and compositions for transdermal administration of antimicrobial medications |
| WO2007004236A2 (en) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| WO2007147043A2 (en) * | 2006-06-16 | 2007-12-21 | Transport Pharmaceutical, Inc. | Pharmaceutical formulations for iontophoretic tetracycline antibiotic delivery |
| US20110097393A1 (en) | 2008-06-25 | 2011-04-28 | US WorldMeade, LLC | Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery |
| EP2365812A4 (en) * | 2008-11-10 | 2012-05-16 | Nitric Biotherapeutics Inc | PHARMACEUTICAL FORMULATIONS FOR THE IONTOPHORETIC DELIVERY OF A CORTICOSTEROID |
| WO2011002776A1 (en) * | 2009-06-29 | 2011-01-06 | Nitric Biotherapeutics, Inc. | Pharmaceutical formulations for iontophoretic delivery of an immunomodulator |
| DK2557924T3 (da) | 2010-04-13 | 2019-09-23 | Relmada Therapeutics Inc | Dermale farmaceutiske sammensætninger af 1-methyl-2',6'-pipecoloxylidid og fremgangsmåde til deres anvendelse |
| SI3086793T1 (sl) | 2013-12-24 | 2022-10-28 | Virginia Commonwealth University | Uporaba oksigeniranih holesterol sulfatov (OCS) za zdravljenje ledvične disfunkcije |
| US11564970B2 (en) | 2017-10-09 | 2023-01-31 | The Broad Institute, Inc. | Compositions and methods for combinatorial drug discovery in nanoliter droplets |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991755A (en) * | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
| US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| JPS6036299B2 (ja) * | 1981-07-02 | 1985-08-20 | タカラベルモント株式会社 | イオン導入器 |
| HU185691B (en) * | 1982-02-09 | 1985-03-28 | Richter Gedeon Vegyeszet | Process for preparing a new analgetic pharmaceutical composition |
| US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4919648A (en) * | 1983-08-18 | 1990-04-24 | Drug Delivery Systems Inc. | High tack drug patch |
| JPS6222662A (ja) * | 1985-07-19 | 1987-01-30 | 林原 健 | イオン導入電子治療器 |
| MY102980A (en) * | 1986-10-31 | 1993-03-31 | Pfizer | Transdermal flux enhancing compositions |
| US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
| CA1331137C (en) * | 1988-02-29 | 1994-08-02 | Pfizer, Inc. | Transdermal flux enhancing compositions |
-
1989
- 1989-11-29 US US07/443,699 patent/US5023085A/en not_active Expired - Fee Related
-
1990
- 1990-11-02 PH PH41182A patent/PH27105A/en unknown
- 1990-11-08 DE DE90312217T patent/DE69006000T2/de not_active Expired - Fee Related
- 1990-11-08 EP EP90312217A patent/EP0435436B1/en not_active Expired - Lifetime
- 1990-11-08 DK DK90312217.4T patent/DK0435436T3/da active
- 1990-11-08 AT AT90312217T patent/ATE99961T1/de not_active IP Right Cessation
- 1990-11-22 IL IL9644990A patent/IL96449A/en not_active IP Right Cessation
- 1990-11-27 CA CA002030943A patent/CA2030943A1/en not_active Abandoned
- 1990-11-27 MY MYPI90002098A patent/MY109727A/en unknown
- 1990-11-27 ZA ZA909512A patent/ZA909512B/xx unknown
- 1990-11-28 KR KR1019900019334A patent/KR930007248B1/ko not_active IP Right Cessation
- 1990-11-28 PT PT96021A patent/PT96021B/pt not_active IP Right Cessation
- 1990-11-28 HU HU907681A patent/HUT55629A/hu unknown
- 1990-11-28 AU AU67069/90A patent/AU613281B1/en not_active Ceased
- 1990-11-28 IE IE428190A patent/IE63597B1/en not_active IP Right Cessation
- 1990-11-28 NZ NZ236253A patent/NZ236253A/xx unknown
- 1990-11-29 JP JP2333509A patent/JPH0688912B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0435436B1 (en) | 1994-01-12 |
| DE69006000T2 (de) | 1994-05-05 |
| KR930007248B1 (ko) | 1993-08-04 |
| EP0435436A3 (en) | 1992-01-08 |
| CA2030943A1 (en) | 1991-05-30 |
| ZA909512B (en) | 1992-06-24 |
| PT96021B (pt) | 1998-02-27 |
| DK0435436T3 (da) | 1994-02-28 |
| ATE99961T1 (de) | 1994-01-15 |
| NZ236253A (en) | 1993-05-26 |
| IE63597B1 (en) | 1995-05-17 |
| HUT55629A (en) | 1991-06-28 |
| KR910009250A (ko) | 1991-06-28 |
| DE69006000D1 (de) | 1994-02-24 |
| AU613281B1 (en) | 1991-07-25 |
| PT96021A (pt) | 1991-09-13 |
| JPH03176426A (ja) | 1991-07-31 |
| JPH0688912B2 (ja) | 1994-11-09 |
| MY109727A (en) | 1997-05-31 |
| IL96449A (en) | 1996-07-23 |
| US5023085A (en) | 1991-06-11 |
| EP0435436A2 (en) | 1991-07-03 |
| IE904281A1 (en) | 1991-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5023085A (en) | Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals | |
| AU2006201898C1 (en) | Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition | |
| JP3784069B2 (ja) | 電気的輸送薬剤分配を増進する組成物 | |
| DE69925105T2 (de) | Iontophoretische vorrichtung enthaltend piperidinderivate | |
| EP0538302B1 (en) | Reduction or prevention of skin irritation by drugs | |
| EP0258392A1 (en) | APPARATUS FOR IONTOPHORETIC ADMINISTRATION OF DRUGS. | |
| JPS61215321A (ja) | 局所薬および全身薬の経皮デリバリー制御組成物および該制御方法 | |
| PT1135188E (pt) | Dispositivo de electrotransporte incluíndo um agente antimicrobiano compatível | |
| US5908400A (en) | Device structure for iontophoresis | |
| JP3261501B2 (ja) | 改善されたイオン導入法による薬剤投与方法 | |
| RU2166315C2 (ru) | Ионтофоретическая доставка противомигреневого препарата |